Luspatercept-aamt
REBLOZYL® (luspatercept-aamt) is the first erythroid maturation agent (EMA) approved by the US Food and Drug Administration and European Union for the treatment of anemia anemia: (uh-NEE-mee-uh) A condition in which
Myelodysplastic Syndromes (MDS)
Elena Solomou, MD, PhD
Institution
Patras University Hospital
Physician Status
accepting new patients
Primary Disease Area of Focus
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Barry Skikne, MD
Institution
Westwood Medical Pavilion and the Richard and Annette Bloch Cancer Care Pavilion
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Dr. Barry Skikne is certified by the American Board of Internal Medicine with a subcertification in hematology. He completed a fellowship at the University of Kansas Medical Center. He earned his medical degree from the University of Witwatersrand and completed his residency at Johannesburg Hospital.
Roberto Ovilla Martinez, MD
Institution
Hospital Angeles Lomas
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Luca Malcovati, MD
Institution
IRCCS S. Matteo Hospital Foundation & University of Pavia
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Dr. Malcovati is an Associate Professor of Hematology at the University of Pavia Medical School and with special interest and expertise in myeloid neoplasms, in particular, myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Dr. Malcovati's research group has made a significant contribution to understanding the molecular basis of myeloid neoplasms and to the integration of somatic mutations in the clinical management of patients.
Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
Introduction: Myelodysplastic Syndrome (MDS) represents a group of cancers characterized by abnormal blood cell formation and maturation, leading to various degrees of cytopenias and potential transformation to acute myeloid leukemia
Evolving therapies for lower-risk myelodysplastic syndromes
The development in the therapeutic landscape of myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik
Targeting TP53 Mutations in Myelodysplastic Syndromes
Mutations in TP53 are observed in ∼20% of patients with myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-P